世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000037620

BRAFキナーゼ阻害薬の世界市場(2024-2028)

TechNavio

Global BRAF Kinase Inhibitors Market 2024-2028

発刊日 2023/12/12

言語英語

体裁PDF/162ページ

ライセンス/価格162ページ

0000037620

Single
Enterprise

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

BRAFキナーゼ阻害薬市場は2023年から2028年に14億米ドル、予測期間中のCAGRは7.88%で成長すると予測されます。このレポートは、全体的な分析、市場規模と予測、傾向、成長ドライバー、課題、および約25のベンダーをカバーするベンダー分析を提供します。

このレポートは、現在の市場シナリオ、最新の傾向と推進力、および全体的な市場環境に関する最新の分析を提供します。市場は、BRAFキナーゼ阻害薬の高い標的親和性と特異性、患者支援プログラムの存在、がんの有病率の増加などによって牽引されています。

調査範囲

  • 市場セグメント
    ➣ 製品別
      ◇ ダブラフェニブ
      ◇ ソラフェニブ
      ◇ ベムラフェニブ
      ◇ エンコラフェニブ
    ➣ 流通チャネル別
      ◇ 病院薬局
      ◇ 小売薬局
      ◇ オンライン薬局
    ➣ 地域別
      ◇ 北アメリカ
      ◇ ヨーロッパ
      ◇ アジア
      ◇ 世界のその他の地域(ROW)

本調査では、今後数年間におけるBRAFキナーゼ阻害薬市場の成長を促進する主な要因の1つとして、BRAFキナーゼ阻害薬における調査領域の拡大を挙げています。また、戦略的提携の拡大やがんに対する意識の高まりも、同市場の大きな需要につながると見込まれています。

BRAFキナーゼ阻害薬市場に関するレポートは、次の分野をカバーしています。

  • BRAFキナーゼ阻害薬市場の規模
  • BRAFキナーゼ阻害薬市場の予測
  • BRAFキナーゼ阻害薬市場の業界分析

堅牢なベンダー分析は、クライアントが市場での地位を向上させるのに役立つように設計されています。

  • 調査企業
    ➣ Asana BioSciences LLC
    ➣ Bayer AG
    ➣ BeiGene Ltd.
    ➣ F. Hoffmann La Roche Ltd.
    ➣ Fore Biotherapeutics Inc.
    ➣ Jazz Pharmaceuticals Plc
    ➣ Nerviano Medical Sciences S.r.l
    ➣ Novartis AG
    ➣ 小野薬品工業(Ono Pharmaceutical Co. Ltd.)
    ➣ Pfizer Inc.
    ➣ Pierre Fabre SA
    ➣ Kinnate Biopharma
    ➣ Black Diamond Therapeutics Inc.

また、本レポートには、市場の成長に影響を与える今後の傾向と課題に関する情報が含まれています。これは、企業が今後のすべての成長機会を戦略化し、活用するのに役立ちます。

この調査は、業界の主要参加者からの意見を含む一次情報と二次情報を客観的に組み合わせて実施されました。このレポートには、主要ベンダーの分析に加えて、包括的な市場とベンダーの状況が含まれています。

このレポートは、利益、価格設定、競争、プロモーションなどの主要なパラメーターの分析による複数のソースからのデータの調査、合成、合計により、市場の詳細な全体像を提示します。業界の主要な影響力を持つ企業を特定することで、さまざまな市場の側面を示します。提示されたデータは包括的で信頼性が高く、一次および二次の両方にわたる広範な研究の結果です。市場調査レポートは、正確な市場の成長を予測するための定性的および定量的調査を使用した、完全な競争状況と詳細なベンダー選択方法論および分析を提供します。

レポート詳細

目次

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size
4.1 Global BRAF kinase inhibitors market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global braf kinase inhibitors market 2018 - 2022 ($ billion)
4.2 Product Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Product Segment 2018 - 2022 ($ billion)
4.3 Type Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Product
6.1 Market segments
Exhibit 30: Chart on Product - Market share 2023-2028 (%)
Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
6.2 Comparison by Product
Exhibit 32: Chart on Comparison by Product
Exhibit 33: Data Table on Comparison by Product
6.3 Dabrafenib - Market size and forecast 2023-2028
Exhibit 34: Chart on Dabrafenib - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Dabrafenib - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Dabrafenib - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Dabrafenib - Year-over-year growth 2023-2028 (%)
6.4 Sorafenib - Market size and forecast 2023-2028
Exhibit 38: Chart on Sorafenib - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Sorafenib - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Sorafenib - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Sorafenib - Year-over-year growth 2023-2028 (%)
6.5 Vemurafenib - Market size and forecast 2023-2028
Exhibit 42: Chart on Vemurafenib - Market size and forecast 2023-2028 ($ billion)
Exhibit 43: Data Table on Vemurafenib - Market size and forecast 2023-2028 ($ billion)
Exhibit 44: Chart on Vemurafenib - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Vemurafenib - Year-over-year growth 2023-2028 (%)
6.6 Encorafenib - Market size and forecast 2023-2028
Exhibit 46: Chart on Encorafenib - Market size and forecast 2023-2028 ($ billion)
Exhibit 47: Data Table on Encorafenib - Market size and forecast 2023-2028 ($ billion)
Exhibit 48: Chart on Encorafenib - Year-over-year growth 2023-2028 (%)
Exhibit 49: Data Table on Encorafenib - Year-over-year growth 2023-2028 (%)
6.7 Market opportunity by Product
Exhibit 50: Market opportunity by Product ($ billion)
Exhibit 51: Data Table on Market opportunity by Product ($ billion)

7 Market Segmentation by Distribution Channel
7.1 Market segments
Exhibit 52: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 53: Data Table on Distribution Channel - Market share 2023-2028 (%)
7.2 Comparison by Distribution Channel
Exhibit 54: Chart on Comparison by Distribution Channel
Exhibit 55: Data Table on Comparison by Distribution Channel
7.3 Hospital pharmacies - Market size and forecast 2023-2028
Exhibit 56: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 57: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 58: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
7.4 Retail pharmacies - Market size and forecast 2023-2028
Exhibit 60: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 62: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
7.5 Online pharmacies - Market size and forecast 2023-2028
Exhibit 64: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 65: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 66: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 67: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Distribution Channel
Exhibit 68: Market opportunity by Distribution Channel ($ billion)
Exhibit 69: Data Table on Market opportunity by Distribution Channel ($ billion)

8 Customer Landscape
8.1 Customer landscape overview
Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 71: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 72: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 73: Chart on Geographic comparison
Exhibit 74: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 UK - Market size and forecast 2023-2028
Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.10 France - Market size and forecast 2023-2028
Exhibit 103: Chart on France - Market size and forecast 2023-2028 ($ billion)
Exhibit 104: Data Table on France - Market size and forecast 2023-2028 ($ billion)
Exhibit 105: Chart on France - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on France - Year-over-year growth 2023-2028 (%)
9.11 Japan - Market size and forecast 2023-2028
Exhibit 107: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 108: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 109: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibit 110: Data Table on Japan - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 111: Market opportunity By Geographical Landscape ($ billion)
Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 113: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 115: Overview on factors of disruption
11.4 Industry risks
Exhibit 116: Impact of key risks on business

12 Vendor Analysis
12.1 Vendors covered
Exhibit 117: Vendors covered
12.2 Market positioning of vendors
Exhibit 118: Matrix on vendor position and classification
12.3 Asana BioSciences LLC
Exhibit 119: Asana BioSciences LLC - Overview
Exhibit 120: Asana BioSciences LLC - Product / Service
Exhibit 121: Asana BioSciences LLC - Key offerings
12.4 Bayer AG
Exhibit 122: Bayer AG - Overview
Exhibit 123: Bayer AG - Business segments
Exhibit 124: Bayer AG - Key news
Exhibit 125: Bayer AG - Key offerings
Exhibit 126: Bayer AG - Segment focus
12.5 BeiGene Ltd.
Exhibit 127: BeiGene Ltd. - Overview
Exhibit 128: BeiGene Ltd. - Business segments
Exhibit 129: BeiGene Ltd. - Key offerings
Exhibit 130: BeiGene Ltd. - Segment focus
12.6 Black Diamond Therapeutics Inc.
Exhibit 131: Black Diamond Therapeutics Inc. - Overview
Exhibit 132: Black Diamond Therapeutics Inc. - Product / Service
Exhibit 133: Black Diamond Therapeutics Inc. - Key offerings
12.7 F. Hoffmann La Roche Ltd.
Exhibit 134: F. Hoffmann La Roche Ltd. - Overview
Exhibit 135: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 136: F. Hoffmann La Roche Ltd. - Key news
Exhibit 137: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 138: F. Hoffmann La Roche Ltd. - Segment focus
12.8 Fore Biotherapeutics Inc.
Exhibit 139: Fore Biotherapeutics Inc. - Overview
Exhibit 140: Fore Biotherapeutics Inc. - Product / Service
Exhibit 141: Fore Biotherapeutics Inc. - Key offerings
12.9 Jazz Pharmaceuticals Plc
Exhibit 142: Jazz Pharmaceuticals Plc - Overview
Exhibit 143: Jazz Pharmaceuticals Plc - Product / Service
Exhibit 144: Jazz Pharmaceuticals Plc - Key news
Exhibit 145: Jazz Pharmaceuticals Plc - Key offerings
12.10 Kinnate Biopharma
Exhibit 146: Kinnate Biopharma - Overview
Exhibit 147: Kinnate Biopharma - Product / Service
Exhibit 148: Kinnate Biopharma - Key offerings
12.11 Nerviano Medical Sciences S.r.l
Exhibit 149: Nerviano Medical Sciences S.r.l - Overview
Exhibit 150: Nerviano Medical Sciences S.r.l - Product / Service
Exhibit 151: Nerviano Medical Sciences S.r.l - Key offerings
12.12 Novartis AG
Exhibit 152: Novartis AG - Overview
Exhibit 153: Novartis AG - Business segments
Exhibit 154: Novartis AG - Key offerings
Exhibit 155: Novartis AG - Segment focus
12.13 Ono Pharmaceutical Co. Ltd.
Exhibit 156: Ono Pharmaceutical Co. Ltd. - Overview
Exhibit 157: Ono Pharmaceutical Co. Ltd. - Product / Service
Exhibit 158: Ono Pharmaceutical Co. Ltd. - Key offerings
12.14 Pfizer Inc.
Exhibit 159: Pfizer Inc. - Overview
Exhibit 160: Pfizer Inc. - Product / Service
Exhibit 161: Pfizer Inc. - Key news
Exhibit 162: Pfizer Inc. - Key offerings
12.15 Pierre Fabre SA
Exhibit 163: Pierre Fabre SA - Overview
Exhibit 164: Pierre Fabre SA - Business segments
Exhibit 165: Pierre Fabre SA - Key offerings
Exhibit 166: Pierre Fabre SA - Segment focus

13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 167: Inclusions checklist
Exhibit 168: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 169: Currency conversion rates for US$
13.4 Research methodology
Exhibit 170: Research methodology
Exhibit 171: Validation techniques employed for market sizing
Exhibit 172: Information sources
13.5 List of abbreviations
Exhibit 173: List of abbreviations

この商品のレポートナンバー

0000037620

TOP